Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab.
暂无分享,去创建一个
J. Braun | J. Brandt | J. Listing | J. Sieper | X. Baraliakos | H. Haibel | M. Rudwaleit | X. Baraliakos | X. Baraliakos | M. Rudwaleit | J. Listing | J. Braun
[1] H. Zeidler,et al. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. , 2005, Rheumatology.
[2] John C. Davis,et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor α receptor fusion protein etanercept , 2005 .
[3] J. Braun,et al. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor α antibody infliximab , 2005 .
[4] B. Dijkmans,et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). , 2005, Arthritis and rheumatism.
[5] D. M. van der Heijde,et al. Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging ( MRI ) – a comparison between contrast enhanced T 1 and short-tau inversion recovery ( STIR ) sequences , 2005 .
[6] D. M. van der Heijde,et al. Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging , 2004, Annals of the rheumatic diseases.
[7] H. Zeidler,et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis , 2004, Annals of the rheumatic diseases.
[8] D. M. van der Heijde,et al. Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems , 2004, Annals of the rheumatic diseases.
[9] P. Voulgari,et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study , 2003, Annals of the rheumatic diseases.
[10] M. Dougados,et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis , 2003, Annals of the rheumatic diseases.
[11] H. Zeidler,et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. , 2003, Arthritis and rheumatism.
[12] D. M. van der Heijde,et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. , 2003, Arthritis and rheumatism.
[13] M. Dougados,et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. , 2002, Rheumatology.
[14] G. Jhangri,et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. , 2002, The Journal of rheumatology.
[15] H. Zeidler,et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial , 2002, The Lancet.
[16] P. Emery,et al. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. , 2001, Arthritis and rheumatism.
[17] M. Stone,et al. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. , 2001, The Journal of rheumatology.
[18] D. Baeten,et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study , 2000, Annals of the rheumatic diseases.
[19] J. Braun,et al. Radiologic diagnosis and pathology of the spondyloarthropathies. , 1998, Rheumatic diseases clinics of North America.
[20] J. Braun,et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. , 1998, Arthritis and rheumatism.
[21] J. Braun,et al. The sacroiliac joint in the spondyloarthropathies , 1996, Current opinion in rheumatology.
[22] A. Calin,et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. , 1994, The Journal of rheumatology.
[23] A. Calin,et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. , 1994, The Journal of rheumatology.
[24] A Calin,et al. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. , 1994, The Journal of rheumatology.
[25] J. Sieper,et al. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. , 1994, Arthritis and rheumatism.
[26] A. Cats,et al. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. , 1984, Arthritis and rheumatism.
[27] A. Calin,et al. Clinical history as a screening test for ankylosing spondylitis. , 1977, JAMA.